AlphaMaven AlphaMaven

Trellis Bioscience Closes $9M Series C

Reported by VC News Daily
Jul 17, 2026· 3 min read
Save Post LinkedIn Email
Key Takeaways
  • • Trellis Bioscience closed a $9 million Series C financing round led by continued support from existing investors New Science Ventures and Easton Capital, with new investors including AMR Action Fund (AMRAF), The Doctor Group of Dallas, and orthopedic surgeons from U.S. centers of excellence.
  • • The funding will advance completion of the Phase 2 clinical trial for calpurbatug (TRL1068), an investigational monoclonal antibody treatment for chronic prosthetic joint infections (PJI), an intractable infectious disease with significant unmet medical need.
  • • Total equity funding now reaches approximately $35 million, matched by equivalent non-dilutive grant support from NIAID and CARB-X, providing a substantial capital base for clinical development and pipeline advancement.
  • • Junjun Gao, PhD, Principal at AMRAF, joined the Trellis Board of Directors as part of the Series C investment, bringing sector expertise to company leadership.
  • • Trellis's proprietary human monoclonal antibody technology, derived from cloning antibodies from recovered patients' white blood cells, extends beyond the lead biofilm disruption program to include antiviral antibodies currently in clinical trials.
Summary
Trellis Bioscience, a clinical-stage biotechnology company headquartered in Redwood City, California, has successfully closed a $9 million Series C financing round to advance its investigational monoclonal antibody (mAb) pipeline targeting intractable infectious diseases. The funding will specifically support completion of the Phase 2 trial for calpurbatug (TRL1068), an mAb candidate designed to treat chronic prosthetic joint infections, a serious complication affecting patients with joint replacement devices that currently lacks effective therapeutic options.

The financing round demonstrates continued confidence from existing backers while broadening the investor syndicate. New Science Ventures and Easton Capital maintained their support, while new investors—AMR Action Fund, The Doctor Group of Dallas, and a consortium of orthopedic surgeons with specialized expertise in PJI from leading U.S. medical centers—joined the round. This strategic mix of institutional and clinical experts reflects the company's focus on addressing a high-need indication with involvement from practitioners at the forefront of the field.

The capital infusion brings Trellis's total equity funding to approximately $35 million, substantially augmented by matched non-dilutive grant support totaling a similar amount from the National Institute of Allergy and Infectious Disease (NIAID) and CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global nonprofit partnership focused on antimicrobial resistance. This combined funding structure—approximately $70 million in total capital—positions the company with substantial resources for clinical development.

Trellis's competitive advantage rests on its proprietary technology for cloning human monoclonal antibodies derived from white blood cells of patients who have recovered from specific infectious diseases. Human antibodies demonstrate lower failure rates due to toxicity compared to other drug classes, a significant advantage in safety-sensitive indications. Beyond the lead biofilm disruption program for PJI, the company's pipeline includes antiviral antibodies, with at least one candidate currently in clinical trials, addressing additional infectious disease opportunities.

As part of the investment, Junjun Gao, PhD, Principal at AMRAF, was appointed to the Trellis Board of Directors, bringing specialized sector knowledge to the company's governance and strategic direction.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

VC News Daily Trellis Bioscience Closes $9M Series C